Compare · AXGN vs STXS
AXGN vs STXS
Side-by-side comparison of Axogen Inc. (AXGN) and Stereotaxis Inc. (STXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and STXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.68B, about 19.0x STXS ($141.3M).
- STXS has been more active in the news (8 items in the past 4 weeks vs 4 for AXGN).
- AXGN has more recent analyst coverage (8 ratings vs 6 for STXS).
- Company
- Axogen Inc.
- Stereotaxis Inc.
- Price
- -
- -
- Market cap
- $2.68B
- $141.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 8
- 6
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Latest AXGN
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- SEC Form 10-Q filed by Axogen Inc.
- Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
- Axogen, Inc. Reports Second Quarter 2026 Financial Results
- Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
- Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Latest STXS
- SEC Form EFFECT filed by Stereotaxis Inc.
- SEC Form EFFECT filed by Stereotaxis Inc.
- SEC Form 424B3 filed by Stereotaxis Inc.
- SEC Form 424B3 filed by Stereotaxis Inc.
- SEC Form 10-Q filed by Stereotaxis Inc.
- Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
- Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
- Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
- University of Szeged Pioneers First Robotic Cardiology Program in Hungary